Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor

doi:10.1186/1471-2407-8-354

BMC Cancer

Volume 8

Viewing options:

Abstract
Full text
PDF (1,016KB)
Additional files

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Montgomery JP
Patterson PH

on PubMed

Montgomery JP
Patterson PH
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor

Jennifer P Montgomery and Paul H Patterson

California Institute of Technology, 1200 E. California Blvd, MC 216-76, Pasadena, CA 91125, USA

author email corresponding author email

BMC Cancer 2008, 8:354doi:10.1186/1471-2407-8-354


Published:	28 November 2008

Additional files

Additional file 1:

The endothelin receptor A-specific antagonist BQ123 does not affect viable cell number in glioma or melanoma cell lines. Cells were treated with BQ123 for 72 h. Values are expressed as means of three replicates ± SEM. Symbols for statistical significance as compared with vehicle-treated controls are displayed at the bottom of the figure and are applicable to all panels.

Format: JPEG Size: 1.1MB Download file